Sign In
Buy UTHR
$549.47
+9.42 (+1.74%)
At Close: Jun 03, 2026
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
11:05am, Wednesday, 23'rd Apr 2025
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
10:46am, Friday, 11'th Apr 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:55am, Friday, 11'th Apr 2025
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Tuesday, 08'th Apr 2025
United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations acr
United Therapeutics: Don't Fear The Patent Expiration Too Much
08:17am, Saturday, 29'th Mar 2025
United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company's revenue is heavily reliant
United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
02:14pm, Wednesday, 26'th Feb 2025
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR ) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Cha
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
12:00pm, Wednesday, 26'th Feb 2025
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates.
United Therapeutics (UTHR) Surpasses Q4 Earnings and Revenue Estimates
08:35am, Wednesday, 26'th Feb 2025
United Therapeutics (UTHR) came out with quarterly earnings of $6.19 per share, beating the Zacks Consensus Estimate of $6.10 per share. This compares to earnings of $4.36 per share a year ago.
United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
06:30am, Wednesday, 26'th Feb 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter
United Therapeutics: A Unique Business With High Margins And Expansion Potential
01:06am, Tuesday, 25'th Feb 2025
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvas
Seeking Clues to United Therapeutics (UTHR) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
10:21am, Monday, 24'th Feb 2025
Besides Wall Street's top -and-bottom-line estimates for United Therapeutics (UTHR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared d
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
11:16am, Thursday, 13'th Feb 2025
United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more
UTHR or ZTS: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 07'th Feb 2025
Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for th
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:51am, Wednesday, 05'th Feb 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
